HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Gourlay, D. Articles by Heit, H. A. PubMed PubMed Citation Articles by Gourlay, D. Articles by Heit, H. A.

Commentary

¹ Pain and Chemical Dependency Division, Wasser Pain Centre, Mount Sinai Hospital, Toronto, Ontario Canada;² Centre for Addiction and Mental Health, Toronto, Ontario Canada;³ Georgetown University School of Medicine, Washington, DC.

^aAddress correspondence to this author at: Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario, Canada M5S 2S1. Fax 416-595-6821; e-mail doug_gourlay@camh.net.

The first 20% of the full text of this article appears below.

This case raises several interesting questions about the clinical role of urine drug testing. First, it is important to distinguish between clinical, patient-centered drug testing, which is done for the patient with informed consent, and regulated or forensic drug testing, which is rarely performed in the best interests of the patient. Clearly, the testing strategy is different in these 2 situations.

This case discussion addresses the all too familiar challenges of end-of-life care that come to bear on the case of a young woman with end-stage cervical cancer. Although her case history is incomplete, it . . . [Full Text of this Article]